Evofem Biosciences Current Ratio 2013-2022 | EVFM

Evofem Biosciences current ratio from 2013 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Evofem Biosciences Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-03-31 $0.02B $0.15B 0.14
2021-12-31 $0.03B $0.14B 0.22
2021-09-30 $0.06B $0.10B 0.58
2021-06-30 $0.10B $0.07B 1.40
2021-03-31 $0.08B $0.08B 1.06
2020-12-31 $0.10B $0.08B 1.27
2020-09-30 $0.10B $0.07B 1.55
2020-06-30 $0.13B $0.06B 2.07
2020-03-31 $0.01B $0.01B 0.95
2019-12-31 $0.03B $0.01B 2.09
2019-09-30 $0.04B $0.02B 2.52
2019-06-30 $0.05B $0.02B 2.84
2019-03-31 $0.00B $0.03B 0.04
2018-12-31 $0.00B $0.03B 0.09
2018-09-30 $0.01B $0.03B 0.54
2018-06-30 $0.02B $0.02B 1.17
2018-03-31 $0.01B $0.03B 0.27
2017-12-31 $0.00B $0.10B 0.02
2017-09-30 $0.01B $0.00B 4.39
2017-06-30 $0.01B $0.00B 4.76
2017-03-31 $0.01B $0.00B 6.25
2016-12-31 $0.01B $0.00B 13.86
2016-09-30 $0.02B $0.00B 10.39
2016-06-30 $0.02B $0.00B 5.96
2016-03-31 $0.03B $0.00B 6.50
2015-12-31 $0.04B $0.01B 4.37
2015-09-30 $0.05B $0.01B 4.35
2015-06-30 $0.06B $0.01B 10.64
2015-03-31 $0.07B $0.00B 17.98
2014-12-31 $0.08B $0.00B 40.26
2014-09-30 $0.00B 0.00
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.01B $0.00B 2.96
2012-12-31 $0.01B $0.00B 6.62
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.004B $0.008B
Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00